InvestorsHub Logo
Followers 16
Posts 2426
Boards Moderated 0
Alias Born 08/15/2006

Re: None

Tuesday, 03/10/2020 11:19:11 AM

Tuesday, March 10, 2020 11:19:11 AM

Post# of 17
Email from IR ... received this morning...

...after dloading their deck, Eddie reached out and asked if I had questions.

I asked about share counts, timelines, transparency, this is the reply...

————

I hope this finds you well! MindMed had an excellent first week of trading after going public on March 3rd, 2020. I’d like to take this opportunity to provide you an update.

Upon our successful listing we had 50 million shares trading hands via 19,000 individual trades, representing $31 million in market value. This helps demonstrate strong liquidity and interest in the alternative pharmaceutical sector.

It has become quite clear that there is an urgency when it comes to the opioid crisis internationally. Our shareholders have expressed that they are impressed with our strategic investors/management, proprietary business model, and the high barriers to entry the Company has established through FDA clinical trials.

Given the current market uncertainty of macro-economic factors such as the coronavirus and OPEC we anticipate and continue to look forward to market improvement over the course of the next few months as more information is uncovered and uncertainty subsides.

JR Rahn, our CEO, took the time last week to visit Yahoo Finance to discuss our go public transaction and how he envisions MindMed as a leader in neuro-pharmaceuticals. If you haven’t watched it yet, I’d strongly encourage you to check it out, as well as some other relevant media - you can do so here.

JR did another great interview with Cheddar you can find here.

Additional Readings

Wall Street Journal Article February 27th, 2020

Fortune Article February 28th, 2020

MindMed Investor Presentation
MindMed Website

Should you have any questions, please do not hesitate to let me know.

When can we schedule a call to discuss the opportunity? I’d be happy to do so.


Best,

Eddie Conley | Investor Relations
e. econley@mindmed.co
w. 647-493-3643
Copyright © 2020 MindMed, All rights reserved.
You are receiving this email because you opted into our content.

Our mailing address is:
MindMed
365 Bay St. Suite 800
Suite 800
Toronto, ON M5H 2V1
Canada

Add us to your address book


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

If you're not living on the edge, your taking up too much space.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.